How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Tixagevimab plus cilgavimab for preventing COVID‑19

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about tixagevimab plus cilgavimab

Marketing authorisation indication

2.1 Tixagevimab plus cilgavimab (Evusheld, AstraZeneca, from now on referred to as tix–cil) has a conditional marketing authorisation for 'the pre-exposure prophylaxis of COVID‑19 in adults who are not currently infected with SARS‑CoV‑2 and who have not had a known recent exposure to an individual infected with SARS‑CoV‑2 and:

  • who are unlikely to mount an adequate immune response to COVID‑19 vaccination, or

  • for whom COVID‑19 vaccination is not recommended.'

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for tixagevimab plus cilgavimab.

Price

2.3 The list price of tixagevimab plus cilgavimab is £800 per 300 mg dose and £1,600 per 600 mg dose (excluding VAT; prices provided by company).

2.4 The company has a commercial arrangement, which would have applied if tixagevimab plus cilgavimab had been recommended.